In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.
AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio.
With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for growth at a meeting with investors and analysts, which it says will be driven ma
